- Home
- RAND vs NRXP Comparison
RAND vs NRXP Comparison
Compare RAND & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | NRXP |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 62.2M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | NRXP |
|---|---|---|
| Price | $11.87 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 3.9K | ★ 516.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $1.58 |
| 52 Week High | $26.00 | $3.84 |
Technical Indicators
Market Signals| Indicator | RAND | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 42.16 |
| Support Level | $10.56 | $1.65 |
| Resistance Level | $12.50 | $2.79 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 85.71 | 36.21 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.